Lumiracoxib
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Gouty Arthritis
Conditions
Acute Gouty Arthritis
Trial Timeline
Jun 1, 2005 → —
NCT ID
NCT00170781About Lumiracoxib
Lumiracoxib is a approved stage product being developed by Novartis for Acute Gouty Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00170781. Target conditions include Acute Gouty Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Gouty Arthritis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00419796 | Approved | Completed |
| NCT00333567 | Approved | Completed |
| NCT00350155 | Approved | Completed |
| NCT00348491 | Approved | Completed |
| NCT00267176 | Approved | Completed |
| NCT00170781 | Approved | Completed |
| NCT00170898 | Approved | Completed |
| NCT00170872 | Phase 3 | Completed |
| NCT00145301 | Phase 3 | Completed |
| NCT00475800 | Phase 3 | Completed |
| NCT00476034 | Phase 3 | Completed |
| NCT00366938 | Phase 3 | Completed |
| NCT00367315 | Phase 3 | Completed |
| NCT00267215 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Gouty Arthritis